Compare Johnson & Johnson (JNJ) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kyndryl Holdings Inc — how do they compare? Johnson & Johnson trades at $259.34 (market cap $626.09B), while Kyndryl Holdings Inc trades at $12.84 (market cap $2.91B). The key difference: Johnson & Johnson is far larger — about 215.2× Kyndryl Holdings Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| JNJ | KD | |
|---|---|---|
Market Cap | $626.09B | $2.91B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $33.14 |
52-Week Low | $172.78 | $10.59 |
Enterprise Value | $654.37B | $5.74B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Kyndryl (KD) trades at $13.63, down 2.78% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company shows improving profitability with 2025 net income of $252M after years of losses, though recent Q1 2027 earnings missed expectations. The acquisition of Healthcare IT Leaders and new AI services demonstrate strategic growth initiatives.
While analyst consensus leans Hold (71%) with a $13.50 price target near current levels, improving cash flow and debt management provide stability. Key risks include revenue declines, ongoing investigations, and competitive pressures in IT services. The stock presents a turnaround story with moderate upside potential balanced by execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
